Q-omics provides the consensus-scored ADGRB3 profile across patient tissues and cancer cell-line models. ADGRB3 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ADGRB3 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, ADGRB3 RNA expression shows 21,188 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where ADGRB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADGRB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADGRB3 survival associations across molecular data types. ADGRB3 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (11) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADGRB3 RNA expression–survival associations across cancer types. High ADGRB3 expression shows unfavorable associations in CESC and UCEC, but favorable associations in KIRC, PAAD, LGG and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for ADGRB3 RNA expression.
This table summarizes ADGRB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ADGRB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADGRB3 shows lower tumor expression in COAD, KIRC, BLCA, LUAD, LUSC and HNSC. The COAD box plot shows higher ADGRB3 RNA expression in normal versus tumor tissue (log2 FC = −0.899, t-test p < 0.001).
This table shows molecular features associated with ADGRB3 in patient tissues and cancer cell lines. In patient samples, ADGRB3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADGRB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
